Baby Born with One Kidney Due to Zofran Use

Another Zofran lawsuit has been filed against GlaxoSmithKline alleging that the drug causes birth defects. G.K., a male child, was born without one kidney. He is also missing the connective tissues that would make a kidney transplant possible. Other birth defects include a deferens that is not fully functional, a defect that may limit G.K.’s sexual function as an adult and make it impossible for him to father a child.

Miracle Recalls Tainted Weight Loss Pill and Male Enhancer

The One Minute Miracle, Inc. recalls two of its products, Miracle Diet 30 and Miracle Rock 48, supplements for weight loss and male enhancement respectively. The recall comes after finding that the products may be tainted with a banned laxative and an analogue to Viagra. Using the products may put consumers in danger. The company urges all consumers to stop using the products immediately. The One Minute Miracle, Inc. is also recalling many of its other products, such as Miracle Cougar Gum, due to safety concerns.

Marcy Borders, 9/11 ‘Dust Lady,’ Dies of Cancer at 42

Borders’s death is a stark reminder that many of those who endured the 9/11 tragedy are suffering from long-term health problems. Borders was asked if she thought that the debris from the terror attack, which contained glass and other carcinogenic dust, among other dangerous particles led to her cancer. She responded, “I’m saying to myself, ‘Did this thing ignite cancer cells in me?’ I definitely believe it because I haven’t had any illnesses. I don’t have high blood pressure, high cholesterol, diabetes.”

Judge Dismisses Part of Plavix Multidistrict False Claims Lawsuit

Judge Freda Wolfson of the U.S. District of New Jersey has granted some relief for drugmakers Bristol-Myers Squibb and Sanofi-Aventis in a complicated multidistrict whistleblower lawsuit against the two companies over marketing claims involving the blood-thinning medication Plavix. Wolfson granted motions to dismiss several claims made by former Sanofi sales representative Elisa Dickson, alleging that

FTC Urges FDA to Re-evaluate Homeopathic Product Regulation

The $3 billion industry has increasingly drawn the attention of both regulators. Among the questions the FDA brought up in the request for comment involve consumer and health provider attitudes towards homeopathic products, requests for data sources regarding the safety of the products, and what kind of measures could be implemented to improve the clarity of the CPG’s standard, among others.

GSK Sells Rights to Autoimmune Drug to Novartis for up to $1 Billion

While the timing of the purchase is ideal in many respects for Novartis considering its portfolio and the pending loss of the gilenya patent, it is also timing that has some in the industry questioning the deal. Ocrelizumab is about two years ahead in development compared to ofatumumab, having completed two successful late-stage studies in June.

Appeals Court Rules in Favor of Labor Department and Home Care Workers

Calling it a “tremendous victory,” Sarah Leberstein, senior staff attorney for the National Employment Law Group said, “Paying workers less than the minimum wage for their work hours, and not paying an overtime premium after 40 hours a week benefits no one.” According to the advocacy group Caring Across Generations, domestic care is one of the U.S.’s lowest paying industry, with an average hourly wage of $9.61.

Fluoroquinolone Antibiotic Neuropathy

Fluoroquinolone antibiotics, such as Cipro and Levaquin, can cause permanent, debilitating side effects. These side effects include fluoroquinolone antibiotic neuropathy, also known as peripheral neuropathy, tendinopathy (the painful inflammation of tendons and tendon rupture. Blurred vision may also occur. In many instances, these side effects persist long after the drugs have been discontinued.

Xarelto Bleeding Risks Equal to Warfarin

A French study shows that the risk of life threatening or uncontrollable bleeding events in patients using Xarelto are no greater than that in patients using Warfarin. However, the study warns that the fact that no reversal agent exists for the effects of Xarelto does not make it safer than Warfarin.

Valeant Buys Sprout Pharmaceuticals, Maker of Just-Approved Female Libido Medication

Valeant’s purchase of Sprout will include $500 million cash up front as well as $500 million when the deal is closed, which is expected to be in early 2016. In addition, Valeant has agreed to give Sprout a portion of future revenues if certain milestones are met, although neither party would discuss specifics. Sprout CEO Cindy Whitehead will join Valeant and lead the division responsible for Addyi.